Pratt Tyrell, Lee Alice, Zheng Jennifer, Tavacoli Faria, Ho Hayley, Liu Tingwei, Zhan Hui, Chen Jingchun
Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, Las Vegas, NV, USA.
School of Integrated Health Sciences, University of Nevada, Las Vegas, Las Vegas, NV, USA.
J Alzheimers Dis. 2025 Aug 8;107(2):13872877251362258. doi: 10.1177/13872877251362258.
BackgroundAlzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline, amyloid plaques, neurofibrillary tangles, and neuroinflammation. Glial cells-astrocytes, microglia, and oligodendrocytes-play essential roles in AD progression, but their pathway-specific genetic contributions remain unclear.ObjectiveTo identify glial cell type-specific biological pathways associated with AD using pathway-based polygenic risk score (PRS) analysis.MethodsWe applied PRSet to evaluate associations between glial-specific pathways and AD in a discovery dataset (ADc1234ADA), adjusting for the top two principal components (Model 1), and additionally for sex, age, and ε4 status (Model 2). Pathways with nominal significance (< 0.05) were further tested in an independent replication dataset (ADNI). Results from both datasets were meta-analyzed and assessed for statistical significance using Bonferroni correction. Competitive -values were used to determine the relative contribution of each pathway within glial types. Genes from significant pathways were used in a follow-up gene-based PRS analysis, following the same modeling and validation steps.ResultsIn Model 1, we identified six significant astrocytic, six microglial, and five oligodendrocyte pathways. In Model 2, five astrocytic and four oligodendrocytic pathways remained significant; no microglial pathways met significance. The top pathways were the immune system in astrocytes, antigen processing in microglia, and transport and trafficking in oligodendrocytes. At the gene level, and were significant in Model 1, while only remained in Model 2.ConclusionsThese findings highlight distinct glia-specific genetic contributions to AD, particularly involving immune-related pathways, and demonstrate the value of cell-type-specific PRS approaches in AD research.
背景
阿尔茨海默病(AD)是一种神经退行性疾病,其特征为认知功能下降、淀粉样斑块、神经原纤维缠结和神经炎症。神经胶质细胞——星形胶质细胞、小胶质细胞和少突胶质细胞——在AD进展中起重要作用,但其特定通路的遗传贡献仍不清楚。
目的
使用基于通路的多基因风险评分(PRS)分析来识别与AD相关的神经胶质细胞类型特异性生物学通路。
方法
我们应用PRSet在一个发现数据集(ADc1234ADA)中评估神经胶质细胞特异性通路与AD之间的关联,对前两个主成分进行校正(模型1),并额外对性别、年龄和ε4状态进行校正(模型2)。具有名义显著性(<0.05)的通路在一个独立的复制数据集(ADNI)中进一步检验。对两个数据集的结果进行荟萃分析,并使用Bonferroni校正评估统计学显著性。竞争P值用于确定每个通路在神经胶质细胞类型中的相对贡献。来自显著通路的基因用于后续基于基因的PRS分析,遵循相同的建模和验证步骤。
结果
在模型1中,我们识别出6条显著的星形胶质细胞通路、6条小胶质细胞通路和5条少突胶质细胞通路。在模型2中,5条星形胶质细胞通路和4条少突胶质细胞通路仍然显著;没有小胶质细胞通路达到显著性。排名靠前的通路是星形胶质细胞中的免疫系统、小胶质细胞中的抗原加工以及少突胶质细胞中的运输和转运。在基因水平上,模型1中[具体基因1]和[具体基因2]显著,而模型2中仅[具体基因1]仍然显著。
结论
这些发现突出了神经胶质细胞特异性遗传对AD的不同贡献,特别是涉及免疫相关通路,并证明了细胞类型特异性PRS方法在AD研究中的价值。